Catalent (CTLT) Tops Q2 EPS by 1c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Catalent (CTLT) Prices Common Share Offering for Gross Proceeds of Approx. $500M
February 4, 2020 5:39 AM ESTCatalent, Inc. (Catalent) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced the pricing of an underwritten public offering (the Offering) of shares of its common stock, which is expected to result in gross proceeds of approximately $500 million, before deducting estimated offering expenses. The underwriters may offer the shares of... More
Catalent (CTLT) to Acquire MaSTherCell Global for $315 Million
February 3, 2020 7:36 AM ESTCatalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, and MaSTherCell Global, Inc., a technology-focused cell and gene therapy contract development and manufacturing organization to leading cell therapy innovators, today announced that Catalent has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. (NASDAQ: ORGS), for an aggregate of $315 million in cash, subject to a customary adjustments.
MaSTherCell extends our leadership position in the... More
